2026– date –
-
Children’s Hospital Los Angeles Joins Multi-Center Trial for In Vivo CRISPR Gene Editing Therapy for Sickle Cell Disease
Children's Hospital Los Angeles (CHLA) Facebook USA Overview Children's Hospital Los Angeles (CHLA) has announced its participation in a multi-center clinical trial evaluating a novel CRISPR-based, direct gene editing therapy for sickle ... -
CRISPR and the Dawn of Germline Editing: Curing Hereditary Disease at the Source
Liv Hospital Turkey Overview Germline genome editing, often referred to as 'baby gene editing,' leverages advanced CRISPR technology to offer a potentially curative approach for monogenic diseases at the embryonic stage. While CRISPR's e... -
CRISPR Gene Editing Achieves Clinical Breakthroughs in Sickle Cell Disease Treatment
Liv Hospital Turkey Overview Clinical trials employing CRISPR gene-editing technology for sickle cell disease are reporting highly promising results, significantly reducing severe vaso-occlusive crises and transfusion dependency. Utilizi... -
Investigational CRISPR Therapy Achieves First Clinical Success in Patient with Drug-Resistant E. Coli, Curing Infection
Clinical Trials Arena Unknown Overview A groundbreaking clinical trial has reported the first successful treatment of a patient with multidrug-resistant E. coli using a CRISPR-based therapy. This innovative treatment directly targeted an... -
CRISPR Cancer Therapy 2026: 32 Clinical Trials Underway, Gene-Edited T-Cells Face Efficacy and Off-Target Challenges
Hirschfeld Oncology USA Overview As of 2026, 32 clinical trials are investigating CRISPR-edited immunotherapies for cancer, predominantly focusing on ex vivo gene-edited immune cells. While these therapies generally demonstrate favorable... -
BioInformant Analyzes the Rise of Exosome Therapeutics in 2026: Potential as a Novel Modality Leveraging Intercellular Communication for New Treatments
BioInformant (Blog) USA Overview BioInformant's blog analyzes the growing role of exosome therapeutics in 2026, highlighting these extracellular vesicles as an emerging treatment modality. Exosomes, lipid bilayer vesicles 30-150 nanomete... -
US FDA Reports Approximately 50% Approval Rate for Regenerative Medicine Advanced Therapy (RMAT) Designations, Totaling 193 Approvals Out of 388 Applications, Highlighting Accelerated Development in Regenerative Medicine
BioInformant (Blog) USA Overview According to a BioInformant blog post, the U.S. FDA has announced the approval of 193 out of 388 total Regenerative Medicine Advanced Therapy (RMAT) designation applications received to date. This indicat... -
University of Wisconsin-Madison Researchers Develop Platform to Identify Host Genes Hindering CRISPR Editing Efficiency, Paving Way for Enhanced Gene Therapy Efficacy
News-Medical.Net USA Overview A research team at the University of Wisconsin-Madison has developed an innovative platform to systematically identify specific host genes that impede the efficiency of CRISPR gene editing. This study provid... -
China’s Xellsmart Secures FDA Fast Track for Off-the-Shelf Stem Cell Therapy XS411 in Parkinson’s Disease, Demonstrating Efficacy in Early-Stage Patients in Chinese Phase 1/2 Trial
Endpoints News China Overview China-based Xellsmart's off-the-shelf stem cell therapy, XS411, for Parkinson's disease, has received FDA Fast Track designation. XS411 aims to replace lost dopamine-producing neurons and restore neurologica... -
FDA Approves Orca-T Precision Treg Cell Therapy, Reducing Chronic GVHD Risk and Boosting Survival in Blood Cancer Patients Undergoing Matched Donor Transplants
AJMC (American Journal of Managed Care) USA Overview The U.S. FDA has approved Orca-T precision Treg cell therapy, designed to reduce the risk of chronic graft-versus-host disease (GVHD) and improve survival rates in blood cancer patient...
